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Abstract
While the interplay between heart failure (HF) and atrial fibrillation (AF) has been extensively studied, little is known regarding
HF and atrial flutter (AFL), which may be managed differently. We reviewed the incidence, prevalence, and predictors of HF in
AFL and vice versa, and the outcomes of treatment of AFL in HF. A systematic literature review of PubMed/Medline and
EMBASE yielded 65 studies for inclusion and qualitative synthesis. No study described the incidence or prevalence of AFL in
unselected patients with HF. Most cohorts enrolled patients with AF/AFL as interchangeable diagnoses, or highly selected
patients with tachycardia-induced cardiomyopathy. The prevalence of HF in AFL ranged from 6% to 56%. However, the
phenotype of HF was never defined by left ventricular ejection fraction (LVEF). No studies reported the predictors, phenotype,
and prognostic implications of AFL in HF. There was significant variation in treatments studied, including the proportion that
underwent ablation. When systolic dysfunction was tachycardia-mediated, catheter ablation demonstrated LVEF normaliza-
tion in up to 88%, as well as reduced cardiovascular mortality. In summary, AFL and HF often coexist but are understudied,
with no randomized trial data to inform care. Further research is warranted to define the epidemiology and establish optimal
management.
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Introduction
Atrial flutter (AFL) is an atrial macro-rentrant tachyar-
rhythmia,1 further subcategorized as cavotricuspid isthmus
(CTI)-dependent and non-CTI-dependent atypical flutter.2
Atrial fibrillation (AF) and AFL often coexist due to shared risk
factors and precipitants. Both rhythms may be a cause or
consequence of heart failure (HF) and are associated with
stroke and increased mortality.3–6 Treatment options for both
rhythms include pharmacologic rate control7,8 and rhythm
control (anti-arrhythmic drugs,8,9 cardioversion,9,10 and
catheter ablation11–13).
Most studies treat AFL and AF as interchangeable
diagnoses.5,14 However, more than 70% of patients with
AFL do not experience AF, and less than 10% with AF are
also diagnosed with AFL.15,16 Furthermore, the distinction
between AF, typical, and atypical AFL is important, as the
risks and success of catheter ablation are markedly
different. For AF, long-term freedom from all recurrent
atrial arrhythmias exceeds 50% with a single procedure,
and approximately 70–80% with multiple procedures,
acknowledging selected cohorts and expertise.17 In small
randomized trials, AF ablation reduced the composite of
death and hospitalization in patients with HF with reduced
ejection fraction.10,11 By contrast, single-procedure ablation
success rates exceed 90% for typical and atypical AFL,2 with
associated acute complication rates of 3–11%.12,13 Ablation
of AFL in unselected patients is associated with decreased
hospitalizations, emergency department visits, development
of subsequent AF,18 and improved quality of life.1,19
Guidelines therefore recommend it as first-line therapy.20
However, few studies included patients with HF, and there
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are no randomized controlled trials in patients with AFL
and HF.
We therefore conducted a systematic review to define the
following: (i) incidence, prevalence, and predictors of HF in
AFL; (ii) incidence, prevalence, predictors, and phenotype of
AFL in HF; (iii) overlap of AFL with AF in HF; (iv) prognosis
of patients with HF and AFL compared with HF and no AFL;
and (v) evidence for treatments of AFL in HF.
Methods
Search strategy
PubMed and EMBASE were searched without date restric-
tion, limited to adult humans and English language, excluding
case studies, reviews, and conference abstracts. The search
strategy combined Medical Subject Headings terms and
keywords in title and abstract to identify HF and AFL
(Supporting Information). Reference lists of included articles
were reviewed for additional citations. English language
studies fulfilling the participant, outcome, and study design
criteria were included. Titles and abstracts were screened
for inclusion, and full texts reviewed by the primary author
(M.J.D.), with confirmation by the supervising author
(N.M.H.). Articles were excluded during full-text review if
they did not report on HF patients, were narrative review
articles, did not report either clinical outcomes or epidemio-
logical estimates, or duplicated previously published data.
Results are synthesized qualitatively due to heterogeneity in
objectives, design, and results.
Results
The search identified 1404 articles in PubMed, 101 unique
articles in EMBASE, and 4 articles added via bibliography re-
view, totalling 1509 records (Figure 1). Of these, 65 met inclu-
sion criteria. Only 10 studies included patients exclusively
with AFL. The remaining 55 studies included both AF and
Figure 1 Flow diagram of study selection. HF, heart failure
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AFL, of which 21 studies reported the proportion with AFL
separately. No study specifically described atypical AFL, and
so all further discussion of AFL relates to either the typical
phenotype or undifferentiated AFL only.
Heart failure in atrial flutter: epidemiology
overview
Twenty-five studies reported the epidemiology of HF in
patients with AFL alone (n = 16) or AFL/AF as a combined
diagnosis (n = 9) (Tables 1 and S1). In all 25 studies, HF was
defined clinically based on the development of typical
symptoms and signs, an existing clinical diagnosis, or admin-
istrative database coding. No study definition specified left
ventricular ejection fraction (LVEF). The prevalence of HF in
hospital or ambulatory populations with AFL ranged from
8% to 56%. The prevalence of HF was higher in patients with
established AFL (14% to 56%) compared with newly diag-
nosed AFL (6% to 28%) (Table 1 and Figure 2). The incidence
rate was between 0.9 and 3.6 per 100 person-years. Potential
factors contributing to the diverse estimates include
differences in arrhythmia duration, setting (inpatient vs.
outpatient), study design (e.g. retrospective vs. prospective),
cohort inclusion criteria, case ascertainment methods, cod-
ing, and indication bias among patients referred for catheter
ablation. Nine studies (Table S1) combined AF and AFL diag-
noses without disclosing the proportion of patients with
AFL, and are not discussed further.5,14,33–39
Heart failure in established atrial flutter
Only three studies examined HF patients solely with
AFL.12,21,22 In a large contemporary US cohort with AFL un-
dergoing ablation (n = 5552), 31% had concurrent HF defined
using administrative data.12 The prevalence of HF in AFL was
even higher in two small historic cohorts: 40% in 110 patients
undergoing ablation (1994–1997) and 56% in 71 patients hos-
pitalized in Atlanta (1966–1970).21,22
Twelve studies included patients with both AF and AFL but
separately reported characteristics of patients with AFL. The
largest study reported HF in 30% of patients with AFL
(n = 20 298), defining the cohort and comorbidities using
International Classification of Disease (ICD) 9 codes in the
US MarketScan claims database.26
Heart failure in newly diagnosed atrial flutter
In patients with newly diagnosed AFL, a higher prevalence of
HF (22% and 28%) was reported in two studies (n = 76 and
n = 181) from the Marshfield Epidemiologic Study Area in
Wisconsin, a comprehensive population-based cohort
defined using inpatient, outpatient, and electrocardiogram
records.28,32 A similar prevalence of comorbid HF (23%) was
observed in 121 patients developing AFL in the Framingham
Heart Study.30 However, another Framingham study using a
nested case-control design reported a lower prevalence of
8% in 112 individuals, the reason for the discrepancy being
unclear.4 Finally, a large Taiwanese national study (n = 6121)
and Canadian provincial registry (n = 9339) of incident AFL
cases identified using administrative records reported lower
rates of HF at 13% and 6%, respectively.15,16
Heart failure in atrial flutter: incidence and
prevalence of heart failure in atrial flutter
compared with atrial fibrillation
Eight studies reported prevalent HF in AFL and AF separately
but within the same cohort and provide insights to their com-
parative frequency (Table 1). The prevalence of HF was similar
in AFL compared with AF in five studies, and notably higher in
three studies (45% vs. 35%,24 14% vs. 6%,23 and 28% vs.
17%28). The two studies from Wisconsin confirmed the higher
prevalence of HF in AFL vs. AF, with adjusted odds ratios rang-
ing from 1.87 to 3.5.28,32 By contrast, in three studies reporting
long-term outcomes, AFL had similar4 or even lower16,31 ad-
justed risk of incident HF or HF hospitalization compared with
AF. However, the latter two studies used administrative data
to define the cohort and outcomes in Taiwan.
Heart failure in atrial flutter: phenotype and
predictors
Only one study characterized the phenotype of HF in patients
with AFL. In a small post-ablation cohort from Boston (n = 36),
patients who developed ‘symptomatic HF’ had slightly lower
mean LVEF at baseline (43 vs. 55%, P = 0.071).23 No study ex-
amined independent predictors of HF in AFL.
Atrial flutter in heart failure: incidence and
prevalence
No study described the incidence or prevalence of AFL in
unselected patients with HF (Table 2), including any of the
major HF registries.
Atrial flutter in heart failure: phenotype and
predictors
No study reported the frequency of AFL phenotype
(i.e. typical or atypical AFL) in HF. However, among the 181 in-
dividuals with new AFL in the Marshfield Epidemiologic Study
Heart failure and atrial flutter 3
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Figure 2 Prevalence of heart failure in patients with incident or prevalent atrial flutter. CI, confidence interval; Prev, prevalence.
Table 2 Characteristics of studies reporting incidence, prevalence, and predictors of AFL/AF in HF
Study (first author, year) Cohort Dates Design n LVEF Inclusion (%) % with AFL
Tachycardia-induced cardiomyopathy
Brembilla-Perrot,40 16 AFL ablation 96–14 Retro cohort 1269 Any 100
Pizzale,41 09 AFL ablation 98–06 Prospect cohort 111 Any 100
Luchsinger,42 98 AFL ablation nr Case series 11 <50% 100
Nerheim,43 04 HF outpatients nr Case series 24 ≤40% 16.7
Jeong,44 08 TICM nr Case control 42 ≤45% 50
Nia,45 11 AF/AFL and LVSD
outpatients
09–10 Case control 387 <40% 15
Hospitalized HF
Wang,46 19 Hospitalized 01–15 Pro cohort 5588 Any nr
Devkota,47 16 Hospitalized 14 Retro cohort 157 <50% nr
von Scheidt,48 14 Hospitalized 09–11 Registry 1853 ≤40% nr
Lund,49 14 KaRen cohort 07–11 Registry multinational 539 ≥45% nr
Sulaiman,50 15 Hospitalized 12 Registry multinational 5005 Any nr
Sasaki,51 13 Hospitalized 10–11 Registry national 8620 Any nr
Sulaiman,52 20 Hospitalized
alcoholic CM
07–14 Registry national 75 430 Any nr






08–13 Trial substudy 750 Any nr
Greene,55 17 ASTRONAUT 09–12 Trial substudy 1358 ≤40% nr
Mentz,56 12 EVEREST 03–06 Trial substudy 4133 ≤40% nr
Pedersen,57 05 TRACE 90–92 Trial substudy 6676 Any nr
Benza,58 04 OPTIME-CHF 97–99 Trial substudy 949 LVSD nr
Pedersen,9 01 DIAMOND 93–97 Trial substudy 506 ≤35% nr
Chronic HF
Hummel,6 13 Outpatients 09–10 Validation study 2467 Any nr
Ibrahim,59 19 Outpatients 08–18 Registry national 1 103 386 Any nr
Gurwitz,60 13 In/outpatient 05–08 Registry national 11 994 Any nr
Zambito 0561 AFL ablation 01–05 Retro cohort 90 <55% 100
Kalscheur,62 17 COMPANION 00–02 Trial substudy 293 ≤35% nr
Swedberg,63 12 EMPHASIS-HF 06–12 Trial substudy 2737 ≤30%/35% nr
Vermes,64 03 SOLVD 86–91 Trial substudy 391 ≤35% nr
AF, atrial fibrillation; AFL, atrial flutter; HF, heart failure; LVSD, left ventricular systolic dysfunction; ms, milliseconds; nr, not reported; pro,
prospective; retro, retrospective; TICM, tachycardia-induced cardiomyopathy.
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Area general population study, 22% of whom had HF,
90% had electrocardiograms consistent with typical
CTI-dependent AFL.32 Similarly, 84% of 1269 patients referred
to a French centre for AFL ablation, 15% of which had prior
HF, presented with ‘counter-clockwise’ AFL.40
Atrial flutter in heart failure: concomitant
diagnosis and subsequent development of atrial
fibrillation
The overlap between AFL and AF in HF is poorly described.
Without specific studies in unselected patients with HF, sev-
eral indirect observations merit consideration. In a US na-
tional outpatient database derived from insurance claims
(n = 484 537), isolated AFL was least common (0.03%), dual di-
agnosis AF/AFL more frequent (0.1%), and lone AF most com-
mon (1.4%).26 However, only a minority of patients in each
group (28–30%) had concurrent HF, defined by ICD-9 codes.
In four studies of highly selected patients with HF/ left ven-
tricular systolic dysfunction (LVSD) and AFL referred for abla-
tion, 33% overall (range 25% to 57%) had concurrent AF
(Table 2).22,43,44,61 Following AFL ablation, AF developed in
17–30% of patients over 350 days to 2 years.22,61 De novo
AF was strongly associated with LVSD following AFL ablation::
43% vs. 14% comparing LVEF < 50% vs. >50%, and 31% vs.
7% for LVEF < 35% vs. 36–55% in two US single-centre
cohorts.22,61 In the remaining cohort and case series studying
tachycardia-induced cardiomyopathy, the small sample sizes
limit meaningful conclusions regarding the overlap.43,44
Atrial flutter in heart failure: prognosis
While 13 studies examined mortality and/or rehospitalization
in AF/AFL as a combined diagnosis, the prognostic implications
of AFL in HF relative to either sinus rhythm or AF have never
been investigated (Table 3; additional details in Table S2).
Atrial flutter in heart failure: treatment
Thirty-one studies described treatment of patients with AF or
AFL, some or all having pre-existing HF or LVSD (Table 4).
From these, 14 studies described the management separately
for AF and AFL patients, of which 5 described electrical car-
dioversion, 10 catheter ablation,8,22,40–45,61,68 and 9 drug
therapy.8,21,24,41,42,65,68,69
For cardioversion, among 19 825 US inpatients with AFL
(16% with existing HF), concurrent HF was associated with
an increased odds of receiving electrical cardioversion during
hospitalization.8 Potential explanations include that decom-
pensated HF prompted cardioversion, anti-arrhythmic drug
options are limited in HF, and greater cardiology specialist in-
volvement in care. Across all studies, early and long-term
maintenance of sinus rhythm after cardioversion ranged from
89% to 96% and 42% to 90%, respectively.36,65,69 The highest
long-term success rate was achieved in 50 Dutch patients, of
whom 16% had ‘cardiomyopathy’ not otherwise defined,
using cardioversion and progressive anti-arrhythmic drugs
with repeat cardioversion if needed.69 Cardioversion had sim-
ilar short-term success (96%) among New Zealand patients
admitted with HF and LVEF ≤ 40%, of whom 46 of 77 had con-
current AFL.68 This was the only study reporting outcomes af-
ter cardioversion or pharmacologic treatment of AFL in
unselected HF patients, with a 1 year all-cause mortality or
rehospitalization rate of 23% following cardioversion. Only
four other studies reported outcomes after cardioversion or
pharmacologic treatment in subgroups with AFL, although
only 16% to 56% had concurrent HF (Table 4).8,21,24,69
In the 10 catheter ablation studies, immediate procedural
success ranged from 87% to 100%, with AFL recurrence of
Table 3 Mortality and hospitalization rates among studies with HF and concurrent AF/AFL
Study






mortality or HFH (%) HFH (%) Follow-up
Mentz,56 12 nr 26a nr nr 30a 24 months
Pedersen,57 05 nr 25a nr nr nr 30 days
Greene,55 17 nr 17 53a nr 31a 12 months
Patel,54 18 nr nr nr 40 nr 60 days
Kalscheur,62 17 nr nr nr 50 at 120 daysa nr 990 days
Swedberg,63 12 nr nrc nrc nrc nrc 4 years
Pederson,9 01 nr nrb nr nr nr 42 months
Rodriguez,65 16 28 12 nr nr nr nr
Ueberham,66 20 nr 1.3 nr nr nr In-hospital (6.2 days)
Aoyama,67 20 nr nr 5 nr 5 20.3 months
Tripathi,12 17 100 nr 18 nr 2 90 days
Lund,49 14 nr nrc nr nr nr 18 months
Hummel,6 13 nr nr nr nrb nr 6 months
AF, atrial fibrillation; AFL, atrial flutter; HF, heart failure; nr, not reported; LVSD, LV systolic dysfunction.
aSignificantly increased from patients in sinus rhythm.
bnr = value not reported, but significant difference from sinus rhythm.
cnr = value not reported, but no significant difference from sinus rhythm.
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5–30% up to 2.3 years.22,45,68 Only the aforementioned non-
randomized New Zealand study described clinical outcomes
in unselected HF patients undergoing ablation, with lower
1 year all-cause mortality or rehospitalization than patients
undergoing cardioversion (8 vs. 23%, P = 0.57).68
Seven studies specifically reported outcomes after treat-
ment in tachycardia-induced cardiomyopathy (with or with-
out ablation or LVSD control groups) — five after catheter
ablation,40–44 and two with pharmacologic rate or rhythm
control (Table 4).43,44 Tachycardia induced cardiomyopathy
was typically defined as LVEF < 40–50% with concurrent
tachyarrhythmia, no alternate aetiology identified, and subse-
quent improvement with arrhythmia control.75 The rates of
LVEF improvement (57% to 100%) or normalization (33% to
88%) appear greater than in unselected patients with HF, with
improvement variably defined as LVEF increase of 5% to 15%,
or to above 40% (Table 4). Factors associated with failed LVEF
recovery included age,40 ischaemic heart disease,40 prior
anti-arrhythmic use,40 lack of heart rate reduction,41,43 and in-
creasing left ventricular end-diastolic diameter.44 AFL-related
tachycardia-induced cardiomyopathy was associated with
lower cardiovascular mortality compared with LVSD unrelated
to AFL among French patients undergoing catheter ablation;
this was the only study that described survival after treatment
of tachycardia-induced cardiomyopathy.40
Discussion
This systematic review has several key findings. First, the inci-
dence and prevalence of HF in patients with AFL is high. Sec-
ond, in unselected patients with HF, remarkably little is
known about AFL—the incidence, prevalence, predictors,
phenotype, overlap with AF, role of imaging, prognostic impli-
cations, and pharmacological treatment have not been de-
scribed. Finally, ablation has mainly been studied in selected
cohorts with tachycardia-induced cardiomyopathy, so the
effectiveness in patients with AFL and HF due to other aetiol-
ogies is unknown. Figure 3 provides a summary of key
findings.
Heart failure in atrial flutter
The incidence and prevalence of HF in AFL was high,
particularly in patients with prevalent AFL (28% to 56% in
six studies). Because many studies enrolled patients undergo-
ing catheter ablation, the most generalizable estimate of HF
prevalence in patients with established AFL was 28% ob-
served in the US MarketScan claims database.26 The preva-
lence of HF in newly diagnosed AFL is likely lower, reported
to be 6–13% in large contemporary cohorts.15,16
Figure 3 Summary of key findings (visual abstract).
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How much of this high prevalence relates to tachyarrhyth-
mia vs. shared risk factors is unclear. The phenotype of HF
including LVEF and aetiology is also uncertain. The finding
of similar or higher risk of developing HF in AFL relative to
AF requires further confirmation. Yet, if the prevalence of
LVSD in AFL is high, then routine assessment of cardiac
function may be appropriate to ensure timely initiation of
guideline-directed medical therapies. The diagnostic yield
and cost effectiveness of such a strategy would require eval-
uation. Additionally, if AFL conveys significantly increased risk
of HF, and this risk is modifiable, then earlier and more ag-
gressive intervention may be warranted. Therapeutic strate-
gies that could be compared include electrical cardioversion
or AFL ablation.
Atrial flutter in heart failure
In the general population, the prevalence of both HF and AF/
AFL is increasing.14,76,77 AFL concurrent with HF will accord-
ingly increase. The implications for health systems need de-
fining, starting with the burden of disease and associated
healthcare utilization including ambulatory and hospital care.
If the prognostic implications of AFL are similar to AF/AFL
considered as a combined diagnosis, then HF hospitalization
may be a marker of further adverse events, and an opportune
time to intervene. Whether arrhythmia is an indicator of risk,
such as a consequence of increasing filling pressures leading
to atrial remodelling and subsequent AFL, or a target for
specific interventions, warrants investigation. It also remains
unclear whether typical AFL may be a consequence of
right-sided HF. While the studies included in this review do
not report phenotype of HF nor right-sided involvement,
studies examining atrial arrhythmias in arrhythmogenic car-
diomyopathy with predominant right ventricular involvement
may provide further insight. Among four studies of arrhyth-
mogenic cardiomyopathy patients (n = 36 to 294),78–81 2–
11% had documented AFL compared with 8–11% with AF,
and 2–19% with both AF and AFL. Atrial arrhythmias were as-
sociated with either right-sided or left-sided ventricular dys-
function or chamber enlargement, but analyses among
patients specifically with AFL were never reported.
There is insufficient evidence to comment on specific ele-
ments of a rate control strategy. However, the early success
of cardioversion was high, as was longer term rhythm control
using anti-arrhythmic drugs in selected studies. Whether the
benefits of ablation in tachycardia-induced cardiomyopathy
extend to HF due to alternate aetiologies also merits study.
This is particularly relevant given the high success rates and
reduction in de novo AF resulting from CTI ablation,18 as well
as the accruing evidence to suggest prognostic benefit
from PVI ablation for concurrent AF and HF.10,11,82 The CAM-
ERA-MRI trial demonstrated greater improvement in ventricu-
lar function after PVI ablation in the absence of ventricular
fibrosis on cardiac MRI.83 Similar studies are warranted in pa-
tients with AFL to develop more personalized treatment
pathways.
Overlap of atrial fibrillation with atrial flutter
The intersection between AF and AFL has two distinct per-
spectives: (i) the prevalence of AFL in patients with AF and
(ii) the prevalence of AF in patients with AFL. Because AF is
approximately 10-fold more common than AFL in the general
population,26 if even a small proportion of patients with AF
have concurrent AFL (e.g. 10%), then a large proportion
of patients with AFL have concurrent AF. The trials of AF in
HF offer another potential view of the overlap between AF
and AFL.82 However, only one study described the proportion
of patients with concomitant AFL (9%).84
The overlap between AFL and AF also merits consideration
when planning ablation for AFL in patients with LVSD, as up
to 43% of whom subsequently develop AF.22 Concurrent PVI
and CTI ablation could be considered without documented
AF in those deemed high risk for future AF. Alternatively,
pulmonary vein triggers for both arrhythmias could be
targeted, as currently being studied in the CRAFT trial.85
However, randomized controlled trials are needed to
examine these strategies in patients with HF before adoption
into clinical practice. Further, in those with multiple arrhyth-
mias amenable to ablation, personalized ablation strategies
chosen from a combination of presenting arrhythmias,
clinical and treatment history, imaging, and mapping may
ultimately yield the best clinical outcomes.
Limitations
Several limitations merit consideration and highlight areas for
further research. Many studies considered AF and AFL as an
interchangeable diagnosis, reflecting the limited accuracy of
ICD coding to distinguish AFL in administrative databases.86
Many HF trials require elevated natriuretic peptide levels
for inclusion, so these patients may be distinct from patients
with AF/AFL enrolled in community-based cohorts or regis-
tries. The significant heterogeneity in study design, popula-
tions, and outcomes prevented quantitative synthesis.
Conclusion
There is limited evidence in all aspects of the intersection be-
tween AFL and HF. Outcomes for these patients are un-
known, and the treatments and processes of care provided
are poorly defined. While previous efforts have largely fo-
cused on AF and HF, future studies need to characterize the
burden of disease and contemporary management of AFL
Heart failure and atrial flutter 9
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and other atrial arrhythmias, compare treatment strategies,
and delineate subgroups that may benefit from more inten-
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Additional supporting information may be found online in the
Supporting Information section at the end of the article.
Table S1. Studies of heart failure in atrial flutter or fibrillation
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Table S2. Characteristics of studies reporting outcomes of pa-
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